Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care
11/2022
Journal Article
Authors:
Rossom, R. C.;
Crain, A. L.;
O'Connor, P. J.;
Wright, E.;
Haller, I. V.;
Hooker, S. A.;
Sperl-Hillen, J. M.;
Olson, A.;
Romagnoli, K.;
Solberg, L.;
Dehmer, S. P.;
Haapala, J.;
Borgert-Spaniol, C.;
Tusing, L.;
Muegge, J.;
Allen, C.;
Ekstrom, H.;
Huntley, K.;
McCormack, J.;
Bart, G.
Volume:
124
Pagination:
107012
Journal:
Contemp Clin Trials
PMID:
36402275
URL:
https://www.ncbi.nlm.nih.gov/pubmed/36402275
Keywords:
Humans Opiate Substitution Treatment/methods *Opioid-Related Disorders/drug therapy *Buprenorphine/therapeutic use Analgesics, Opioid/therapeutic use Primary Health Care Opioid overdose Opioid use disorder
Pragmatic clinical trial Primary care Shared decision-making
Abstract:
ACKGROUND: Opioid-related deaths continue to rise in the U.S. A shared decision-making (SDM) system to help primary care clinicians (PCCs) identify and treat patients with opioid use disorder (OUD) could help address this crisis. METHODS: In this cluster-randomized trial, primary care clinics in three healthcare systems were randomized to receive or not receive access to an OUD-SDM system. The OUD-SDM system alerts PCCs and patients to elevated risk of OUD and supports OUD screening and treatment. It includes guidance on OUD screening and diagnosis, treatment selection, starting and maintaining patients on buprenorphine for waivered clinicians, and screening for common comorbid conditions. The primary study outcome is, of patients at high risk for OUD, the percentage receiving an OUD diagnosis within 30 days of index visit. Additional outcomes are, of patients at high risk for or with a diagnosis of OUD, (a) the percentage receiving a naloxone prescription, or (b) the percentage receiving a medication for OUD (MOUD) prescription or referral to specialty care within 30 days of an index visit, and (c) total days covered by a MOUD prescription within 90 days of an index visit. RESULTS: The intervention started in April 2021 and continues through December 2023. PCCs and patients in 90 clinics are included; study results are expected in 2024. CONCLUSION: This protocol paper describes the design of a multi-site trial to help PCCs recognize and treat OUD. If effective, this OUD-SDM intervention could improve screening of at-risk patients and rates of OUD treatment for people with OUD.
